Short Interest in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Declines By 40.0%

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXHGet Free Report) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 900 shares, a drop of 40.0% from the December 31st total of 1,500 shares. Based on an average daily trading volume, of 2,300 shares, the short-interest ratio is currently 0.4 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Performance

First Trust Nasdaq Pharmaceuticals ETF stock traded down $0.13 during trading hours on Friday, reaching $27.74. 3,160 shares of the stock were exchanged, compared to its average volume of 2,518. First Trust Nasdaq Pharmaceuticals ETF has a 52-week low of $25.73 and a 52-week high of $29.72. The stock has a market cap of $15.26 million, a P/E ratio of 15.98 and a beta of 0.70. The firm’s 50 day moving average is $27.46 and its 200 day moving average is $28.22.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, December 31st. Investors of record on Friday, December 13th were given a $0.1304 dividend. The ex-dividend date of this dividend was Friday, December 13th. This is an increase from First Trust Nasdaq Pharmaceuticals ETF’s previous dividend of $0.13.

About First Trust Nasdaq Pharmaceuticals ETF

(Get Free Report)

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.

Featured Stories

Receive News & Ratings for First Trust Nasdaq Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust Nasdaq Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.